Loading company
Loading
Latest annual · FY2025
Millions- Total revenues
- 812
- Operating income
- 45
- Net income
- (68)
Latest quarter · Q3 FY2026
Millions- Free cash flow
- (40)
Caris Life Sciences, Inc. (CAI) financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2025 | FY2024 | Change | Source |
|---|---|---|---|---|
| Revenue | $812 million | $412.3 million | +97% | 10-K 2026-03-03 · proof |
| Operating income | $45.1 million | -$257.1 million | 10-K 2026-03-03 · proof | |
| Net income | -$68.1 million | -$281.9 million | 10-K 2026-03-03 · proof | |
| Cash from operating activities | $83.2 million | -$245.2 million | 10-K 2026-03-03 · proof | |
| Free cash flow | $66.9 million | -$253.6 million | 10-K 2026-03-03 · proof | |
| Total assets | $1.1 billion | $343.7 million | +227.5% | 10-K 2026-03-03 · proof |
| Total liabilities | $548.4 million | $620.9 million | -11.7% | 10-K 2026-03-03 · proof |
| Cash and cash equivalents | $796.3 million | $64 million | +1,145.2% | 10-K 2026-03-03 · proof |
| Total debt | $379 million | $379.5 million | -0.1% | 10-K 2026-03-03 · proof |
- What was Caris Life Sciences, Inc. (CAI)'s revenue in fiscal 2025?
- Caris Life Sciences, Inc. (CAI) reported revenue of $812 million for fiscal 2025 (the year ended Dec 31, 2025), against $412.3 million the year before (+97%). Source: the 10-K filed with the SEC on Mar 3, 2026. SEC
- What was Caris Life Sciences, Inc. (CAI)'s operating income in fiscal 2025?
- Caris Life Sciences, Inc. (CAI) reported operating income of $45.1 million for fiscal 2025 (the year ended Dec 31, 2025), against -$257.1 million the year before. Source: the 10-K filed with the SEC on Mar 3, 2026. SEC
- What was Caris Life Sciences, Inc. (CAI)'s net income in fiscal 2025?
- Caris Life Sciences, Inc. (CAI) reported net income of -$68.1 million for fiscal 2025 (the year ended Dec 31, 2025), against -$281.9 million the year before. Source: the 10-K filed with the SEC on Mar 3, 2026. SEC
- What was Caris Life Sciences, Inc. (CAI)'s cash from operating activities in fiscal 2025?
- Caris Life Sciences, Inc. (CAI) reported cash from operating activities of $83.2 million for fiscal 2025 (the year ended Dec 31, 2025), against -$245.2 million the year before. Source: the 10-K filed with the SEC on Mar 3, 2026. SEC
- What was Caris Life Sciences, Inc. (CAI)'s free cash flow in fiscal 2025?
- Caris Life Sciences, Inc. (CAI) reported free cash flow of $66.9 million for fiscal 2025 (the year ended Dec 31, 2025), against -$253.6 million the year before. Source: the 10-K filed with the SEC on Mar 3, 2026. SEC
- What are Caris Life Sciences, Inc. (CAI)'s total assets?
- As of Dec 31, 2025, Caris Life Sciences, Inc. (CAI) reported total assets of $1.1 billion, against $343.7 million a year earlier (+227.5%). Source: the 10-K filed with the SEC on Mar 3, 2026. SEC
- What are Caris Life Sciences, Inc. (CAI)'s total liabilities?
- As of Dec 31, 2025, Caris Life Sciences, Inc. (CAI) reported total liabilities of $548.4 million, against $620.9 million a year earlier (-11.7%). Source: the 10-K filed with the SEC on Mar 3, 2026. SEC
- What are Caris Life Sciences, Inc. (CAI)'s cash and cash equivalents?
- As of Dec 31, 2025, Caris Life Sciences, Inc. (CAI) reported cash and cash equivalents of $796.3 million, against $64 million a year earlier (+1,145.2%). Source: the 10-K filed with the SEC on Mar 3, 2026. SEC
- What is Caris Life Sciences, Inc. (CAI)'s total debt?
- As of Dec 31, 2025, Caris Life Sciences, Inc. (CAI) reported total debt of $379 million, against $379.5 million a year earlier (-0.1%). Source: the 10-K filed with the SEC on Mar 3, 2026. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=ticker:CAI&period_type=annual&limit=5"Information only, not investment advice.